Technophage has been featured in the recent article “The 7 Biotech Companies in Portugal You Should Know About in 2024” by Labiotech! This recognition is a validation to our team’s hard work, dedication, and innovative spirit in advancing biotechnology throughout the years. We are proud to be part of such a dynamic and forward-thinking industry, and we are committed to continuing our mission of making a positive impact on global health.With our bacteriophage-based product TP-102 in phase 2 clinical trial and two additional products, TP-122 and TZ-161, reaching the clinical stage, we are closer than ever to presenting specific solutions to patients in need.
Thank you to Labiotech for this honor and to our incredible team and partners for their support.